Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 6/20 | 0.48 |
| ▸ | TP53 | P04637 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13290981 | 0.90 | MAPT (0.51) | APPTP53LMNAMAPTTHRB | |
| SCHEMBL3038362 | 0.90 | MAPT (0.51) | APPTP53LMNAMAPTTHRB | |
| SCHEMBL3049445 | 0.86 | APP (0.48) | APPTP53LMNAMAPTTHRB | |
| SCHEMBL774397 | 0.86 | APP (0.49) | APPTP53LMNAMAPTTHRB | |
| SCHEMBL3045448 | 0.85 | APP (0.48) | APPTP53LMNAMAPTSMN1; SMN2 | |
| SCHEMBL3042345 | 0.85 | APP (0.48) | APPTP53LMNAMAPTSMN1; SMN2 | |
| SCHEMBL3042610 | 0.84 | LMNA (0.42) | APPTP53LMNAMAPTSMN1; SMN2 | |
| SCHEMBL772551 | 0.83 | TP53 (0.61) | APPTP53LMNAMAPTTHRB | |
| SCHEMBL3049440 | 0.79 | LMNA (0.53) | APPTP53LMNAMAPTTHRB | |
| SCHEMBL13290974 | 0.78 | LMNA (0.51) | APPTP53LMNAMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100150833-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC | 2010-06-17 | — | — | US | disclosed |
| US-20100143253-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100143251-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC | 2010-06-10 | — | — | US | disclosed |
| US-7700616-B2 | Compounds and amyloid probes thereof for therapeutic and imaging uses | MOLECULAR NEUROIMAGING, LLC. (US) | 2010-04-20 | — | — | US | disclosed |
| EP-2023919-A2 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | Molecular Neuroimaging, LLC (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008118122-A2 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC (US) | 2008-10-02 | — | — | WO | disclosed |
| US-20070258887-A1 | Compounds and amyloid probes thereof for therapeutic and imaging uses | MOLECULAR NEUROIMAGING, LLC. | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258887-A1 | Compounds and amyloid probes thereof for therapeutic and imaging uses | APP, BACE1, BACE2 | APP 1/4885TP53 499/4885LMNA 481/4885 |
| US-20100143253-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | APP, BACE1, BACE2 | APP 1/4885TP53 499/4885LMNA 481/4885 |
| US-20100150833-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | APP, BACE1, BACE2 | APP 1/4885TP53 499/4885LMNA 481/4885 |
| US-20100143251-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | APP, BACE1, BACE2 | APP 1/4885TP53 499/4885LMNA 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.